The selling of the call is a strategy to increase profit and has nothing to do anticipating events....that was the gist of it...and you try to give us a whole thesis on it.
Wheeler and Shea predicted quite accurately the FDA's imminent approval of Enoxaparin. Not sure their generic Copaxone prediction would be any less accurate.
I must have missed something though. What have they been predicting?